China no longer relies on the nationwide mass testing and strict centralized quarantine used during its zero-COVID period. Current guidance instead describes testing based on need and risk, while surveillance tracks COVID-19 alongside other respiratory illnesses.
That distinction matters because rules from 2020 to 2022 don’t describe China’s current approach, and local measures can change over time. For context on how health officials monitor outbreaks, see how China CDC tracks viruses and reports outbreaks.
Key Takeaways
- China has shifted away from zero-COVID mass testing and centralized quarantine. Current guidance describes testing based on need and risk.
- China CDC monitors SARS-CoV-2 through sentinel surveillance, testing outpatient and hospitalized patients alongside other respiratory pathogens.
- In August 2026, China reported 771,000 confirmed cases, 640 severe cases, and six deaths. These reported cases don’t measure every infection.
- Case totals depend on testing and reporting, so they don’t show the full spread. For international context, WHO’s COVID-19 dashboard tracks reported data across countries.
How China Handles COVID-19 Cases and Outbreaks Today
China now uses routine respiratory surveillance and testing based on need and risk, rather than the population-wide screening associated with zero-COVID. Understanding the current approach requires separating the late-2022 policy shift from what national guidance confirms today.
How China moved away from zero-COVID
For much of the pandemic, China relied on frequent mass PCR testing, contact tracing, movement limits, and centralized quarantine to suppress transmission. These controls could affect entire cities or neighborhoods, even when outbreaks were concentrated in particular areas.
The government began easing restrictions on November 11, 2022, with a package known as the “20 Measures.” The changes narrowed some quarantine and contact-tracing requirements and called for more targeted controls.
They were followed on December 7 by the “10 Measures,” which dismantled many remaining controls, including routine mass testing and broad movement restrictions. The shift replaced centralized quarantine in many situations with home isolation. These were historical policy changes, not a description of current rules. A review of China’s December 2022 policy shift describes how quickly the former system was rolled back.
After that transition, outbreak response moved toward testing and precautions aimed at specific settings or higher-risk groups. That differs from the earlier approach, when testing and movement controls could apply broadly across a population. The distinction also matters when reading older accounts of China’s pandemic response: rules from the zero-COVID period should not be treated as current policy.
What the current policy does and does not confirm
National Health Commission guidance updated in August 2026 says residents can be tested as needed and that universal nucleic-acid screening is no longer conducted. The guidance describes different testing strategies for different groups, with attention to detecting infections among people at higher risk of severe illness. During an outbreak, it favors individual nucleic-acid testing over pooled testing.
Some settings have more specific provisions. For example, the guidance calls for weekly testing of staff and people receiving care in elder-care and social-welfare facilities during an epidemic. People with fever or respiratory symptoms should be tested promptly. If an infection is detected in a facility, the guidance calls for timely testing there, with follow-up based on results and risk assessment.
China also continues to monitor COVID-19 through routine respiratory surveillance. China CDC’s sentinel system tests samples from outpatient and emergency patients with influenza-like illness, as well as hospitalized patients with severe acute respiratory infection. In October 2026, the system tested for SARS-CoV-2 alongside other respiratory pathogens. Because this is surveillance of selected patients, and not universal screening, reported case totals don’t capture every infection. Recent reported COVID-19 increases in China should be read in that context.
The available national guidance does not establish a single mandatory isolation period for everyone with COVID-19, a general home-isolation requirement, or a current national travel restriction. It also doesn’t confirm one national treatment protocol or eligibility rule. Those details shouldn’t be inferred from rules issued during zero-COVID or presented as current nationwide requirements without dated, authoritative guidance.
How China Tracks COVID-19 and Decides Who Gets Tested
China tracks COVID-19 through routine respiratory surveillance and tests people according to symptoms, exposure, setting, and risk. These methods help officials follow changes in infection activity, but they don’t count every case across the country.
Sentinel clinics and hospitals watch for respiratory illness
China CDC’s acute respiratory-infection sentinel system tests samples from selected patients who seek care for influenza-like illness in outpatient or emergency settings. It also tests hospitalized patients with severe acute respiratory infection. By including SARS-CoV-2 in a broader panel, the system can track COVID-19 alongside flu and other respiratory pathogens. China CDC’s sentinel-surveillance reporting describes this approach.
In the report covering October 12 to 18, 2026, SARS-CoV-2 appeared among the pathogens tested. The same surveillance program also monitored viruses and bacteria such as influenza, respiratory syncytial virus (RSV), adenovirus, and Mycoplasma pneumoniae.
That wider view helps public health officials assess which illnesses are circulating among patients who need medical care. It also puts COVID-19 activity in context with other causes of respiratory symptoms. China’s respiratory virus surveillance findings illustrate why tracking several pathogens together matters.
Testing is targeted to need and risk
China’s current guidance distinguishes testing people who have symptoms or a relevant exposure from screening an entire population. Residents can be tested as needed, and the guidance says universal nucleic-acid screening is no longer conducted. A person with fever or respiratory symptoms may need testing, while a facility or local response may target people based on exposure and the setting’s risk.
The guidance also directs testing strategies toward finding infections among people at higher risk of severe illness. For example, it includes more specific testing provisions for elder-care and social-welfare facilities during an epidemic. If an infection is identified in one of these settings, testing can extend to people there, with later testing shaped by results and risk assessment.
During an outbreak, the guidance says testing should primarily use individual samples, rather than pooled testing. Individual results can help identify who is infected and guide follow-up. This is different from population-wide screening, which tests large groups regardless of symptoms or known exposure.
What reported case numbers can tell readers
China’s August 2026 report, published September 18, recorded 771,000 confirmed cases, 640 severe cases, and six deaths across mainland provincial-level regions and the Xinjiang Production and Construction Corps. The report described the case trend as fluctuating downward.
Those figures summarize reported cases, not every infection. The report data provided no testing denominator, so readers cannot tell how many people were tested or calculate what share of infections the total captured. People who were never tested, including those with mild or no symptoms, may not appear in the reported count.
For that reason, these figures should not be compared directly with numbers collected during periods of population-wide testing. Changes in testing practices affect how many cases officials detect and report. The totals offer a dated snapshot of documented illness and outcomes, while sentinel surveillance offers a separate view based on selected patients receiving care. Neither measure alone provides a complete count of infections nationwide.
What Happens When COVID-19 Is Found in a High-Risk Setting
Elder-care and social-welfare facilities need to identify possible infections quickly because residents may face a greater risk of severe illness. China’s National Health Commission guidance sets out testing steps for these settings during an epidemic, while leaving follow-up testing responsive to the results and assessed risk.
Testing rules for elder-care and social-welfare facilities
During an epidemic, the guidance calls for weekly testing of facility staff and people receiving care. Facilities can use antigen tests or nucleic-acid tests for people in care. Staff testing is also weekly, with test type determined according to the guidance and local implementation.
People who develop a fever or respiratory symptoms should be tested promptly rather than waiting for the next routine testing round. That gives the facility a way to check a new illness as it appears, while regular testing provides a recurring check during an epidemic.
If a COVID-19 infection is detected, the guidance calls for timely testing of everyone in the facility. That expands testing beyond the person whose infection was first found, helping establish whether other infections may also be present. Subsequent testing depends on the initial results and a risk assessment, rather than a single fixed schedule stated for every facility.
These provisions are part of national operational guidance. They describe a testing approach, but the available guidance does not establish that every facility or locality must apply identical procedures in every circumstance.
How facilities can limit further spread
Prompt testing helps a facility identify additional cases that might otherwise go unnoticed, including infections among people without reported symptoms. Testing after a case is found can give staff and health authorities a clearer picture of whether the infection appears isolated or may involve others in the setting.
The next testing round can then respond to what the results show. If testing identifies more infections, the facility has information to reassess risk; if it finds no additional cases, that result also informs whether and when further testing is needed. The guidance leaves the timing of later tests dependent on results and risk assessment, rather than prescribing one universal sequence.
This distinction matters when describing China’s current outbreak response. The guidance supports testing to detect possible cases and adjust follow-up as risk changes. It does not, in the material available here, confirm a nationwide rule that every facility must impose visitor limits, close, isolate residents by room, or quarantine contacts after a positive result. Specific measures should not be assumed without current, local instructions that confirm them.
Vaccination, Medical Care, and Local Response: What Is Known
China’s current COVID-19 guidance supports vaccination as a preventive measure, but the available extract doesn’t spell out a national schedule or eligibility criteria. It also leaves important details about treatment and emergency response unspecified, so readers should avoid treating older rules or local actions as nationwide policy.
Vaccination remains part of prevention
The surfaced National Health Commission guidance recommends vaccination to help prevent COVID-19. However, the extract doesn’t provide a current national schedule, vaccine product list, booster interval, age group, or eligibility rules. Those details shouldn’t be inferred from past recommendations or other countries’ guidance.
For personal decisions, check current information from the relevant health authority. The National Health Commission’s official website is a place to look for published national updates, though local guidance may address circumstances in a particular area.
Avoid assuming one treatment or isolation rule applies nationwide
The current-source material available here doesn’t set out a national COVID-19 treatment protocol, name antiviral products, or give a general treatment eligibility rule. It also doesn’t establish a mandatory isolation period or a general requirement for home isolation.
That absence matters when reading older coverage. Policies from the zero-COVID period, or measures adopted in response to a particular outbreak, don’t by themselves show what applies nationwide now. Anyone who is ill or concerned about possible exposure should contact a qualified medical professional and check current local health authority guidance before making care or isolation decisions.
Local measures can change with risk
National guidance documents some surveillance and testing practices. China CDC’s sentinel system tests selected patients with respiratory symptoms and hospitalized patients with severe respiratory illness. National guidance also describes targeted testing in settings such as elder-care and social-welfare facilities during an epidemic. These provisions show how testing can help monitor illness and identify cases in higher-risk settings.
They don’t establish a current national COVID emergency threshold or a nationwide lockdown or travel-restriction policy. The reviewed material also doesn’t specify when authorities must activate broader emergency powers. Local authorities may issue instructions as conditions change, but the available sources don’t confirm that any particular emergency measure applies across China today.
For readers tracking an outbreak, the clearest distinction is between documented surveillance and setting-specific testing guidance and broader restrictions that require separate, current confirmation. Check local health authority announcements for area-specific instructions, and treat claims of a nationwide rule cautiously unless a dated official source supports them.
Frequently Asked Questions
China’s COVID-19 policies have changed substantially since the zero-COVID period, so older reports may not describe current practice. These answers clarify what current guidance and reporting establish, and where readers should check for local updates.
Does China still test everyone for COVID-19?
No. Current national guidance says China no longer conducts universal nucleic-acid screening. Instead, testing is based on need and risk, such as symptoms, exposure, or the possibility of severe illness.
Does China still use zero-COVID lockdowns?
China substantially dismantled its strict zero-COVID system in December 2022, ending the policy framework associated with widespread testing and broad movement controls. That history does not confirm what every locality does today, so check current local notices before assuming a particular restriction applies.
Are COVID-19 cases still reported in China?
Yes. China CDC continues to publish reports of confirmed COVID-19 cases and related outcomes. Those totals reflect infections that were confirmed and reported, not every infection in the population; testing and surveillance methods affect what appears in the count. Reports on COVID-19 variant surveillance also show why case totals alone cannot describe every aspect of viral activity.
What happens if someone tests positive in an elder-care facility?
When an infection is detected, the guidance calls for timely testing of everyone in the facility. Follow-up testing should then reflect the results and an assessment of risk, rather than a fixed schedule for every situation. People with fever or respiratory symptoms should be tested promptly.
Is there a single national isolation period for COVID-19?
The current sources described here do not establish a single mandatory national isolation period. Because local instructions may differ or change, people who test positive should check current guidance from the relevant local health authority.
Where can travelers check for current rules?
Before departure, check current notices from Chinese health authorities and the local government for the destination, along with your own government’s travel advisories. For U.S. travelers, the State Department’s China travel advisory provides current travel information; it does not, by itself, establish a COVID-specific entry rule.
